High pressure Shot Cell Disruptorview on SAM.gov

General Information Document Type: Presolicitation Synopsis Number: 75N98026Q00736 Posted Date: July 2, 2026 Original Response Date: July 13, 2026 Current Response Date: July 13, 2026 Set Aside: N/A NAICS Code: 334516 Contracting Office Address National Institutes of Health (NIH), Office of the Director (OD) Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM) Hospital and Laboratory Support Division 6701 Rockledge Drive Bethesda, MD 20817 Description INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Constant Systems LTD 11 Low March Industrial Estate Low March, Daventry NN11 4SD GBR NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 334516 with a Size Standard $1000. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: High pressure Shot Cell Disruptor Background Information: The National Institute of Diabetes and Digestive and Kidney Diseases conducts protein purification and characterization studies involving membrane proteins, including outer membrane proteins from Gram-negative bacteria. These studies require efficient cell disruption methods that preserve protein structure, membrane integrity, and sample quality for downstream structural and functional analyses. The institute also performs bacterial cell fractionation procedures that require isolation of intact outer membrane fractions for research applications. Conventional cell disruption methods, such as sonication and bead-beating, can introduce excessive shear forces, uneven energy transfer, and heat generation that may damage proteins and membrane structures. To support ongoing research activities, the National Institute of Diabetes and Digestive and Kidney Diseases requires a high-pressure homogenization system capable of providing controlled, reproducible cell disruption while maximizing sample recovery and minimizing processin…